Fig. 7: In vivo therapeutic efficiency of targeted and non-targeted nanoparticles evaluated in MM NSG mouse model. | Blood Cancer Journal

Fig. 7: In vivo therapeutic efficiency of targeted and non-targeted nanoparticles evaluated in MM NSG mouse model.

From: BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma

Fig. 7

Therapeutic effect of vehicle control, BTZ, BTZ-NPs, and BCMA-BTZ-NPs on myeloma xenograft growth and survival. A BCMA-BTZ-NPs significantly delayed tumor growth as compared with BTZ-NPs (p < 0.0001). B BCMA-BTZ-NPs enhanced survival with respect to non-targeted NPs (p < 0.01) and free drug (p < 0.01), as shown in Kaplan-Meier survival plot. C Images of representative mice from different groups and respective tumor from each group treated with vehicle, free drug BTZ, BTZ-NPs and BCMA-BTZ-NPs. D Body weight for different treatment groups was monitored over the indicated time periods. E Analysis of histopathological morphology, by HE staining of liver, lung, and kidney extracted from mice who received different treatments to compare treatment effect on major organs. (Magnification of each panel 40×). Mean ± SD of 2-5 independent experiments performed in triplicate, ns not significant, ****p < 0.0001,***p < 0.001, **p < 0.01, *p < 0.05, significance analyzed by one-way ANOVA followed by Tukey’s post hoc test.

Back to article page